DT03 Rec'd PCT/PTO .0 7 JAN 2005

	Express Mail Label Number	Date of D	eposit ;								
Form PTO- (REV 10-96		and Trademark Office	ATTORNEY'S DOCKET NUMBER								
	TRANSMITTAL LETTER TO THE UNITED STATE DESIGNATED/ELECTED OFFICE (DO/EO/US CONCERNING A FILING UNDER 35 U.S.C. 3	S)	DV 4 – 33620A U.S. APPLICATION NO. (If known, see 37 CFR 1.5)  10/520730.								
	NATIONAL APPLICATION NO. INTERNATIONAL F P03/06766 June 26, 2003	PRIORITY DATE CLAIMED July 8, 2002									
	OF INVENTION ETED POLYPEPTIDE SPECIES ASSOCIATED WITH CAR	DIOVASCULA	R DISORDERS								
	CANT(S) FOR DO/EO/US UELERET, ET AL.										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
4. ⊠ 5. ⊠ 6. □ 7. ⊠	<ul> <li>☑ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>☑ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>☑ A copy of the International Application as filed (35 U.S.C. 371(c)(2))</li> <li>a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. ☐ has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> <li>c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).</li> <li>☐ A translation of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).</li> <li>a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. ☐ have been transmitted by the International Bureau.</li> <li>c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. ☐ have not been made and will not be made.</li> <li>☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>☐ An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).</li> <li>A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C.</li> </ul>										
371(c)(5)).   (Items 11. to 16. below concern document(s) or information included.											
11. 🔲	An Information Disclosure Statement under 37 CFR 1.97 and 1.9	98.									
12. 🗌	☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
13.	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.										
14.	A substitute specification.										
15. 🔲	A change of power of attorney and/or address letter.										
16. 🛛	3.   Other items or information: Application Data Sheet, Unexecuted Declaration										

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

U.S. APPLICATION NOT know 5	ATIONNO Kny 5867 (177) TO INTERNATIONAL APPLICATION NO. PCT/EP03/06766 DV 4-330			DOCKET NUMBER								
		id:				CALC	UI ATION	S PTO USE ONLY				
17.  The following fees are submitted:  BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):								- 110 doc o				
Search Report has been prepared by the EPO or JPO												
International preliminary examination fee paid to USPTO (37 CFR 1.482)												
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$												
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$												
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$												
ENTER APPROPRIATE BASIC FEE AMOUNT =												
Surcharge of \$130 for fu months from the earliest				□ 30		\$						
CLAIMS	NUMBER		NUMBER EXTRA		RATE							
Total claims	13	- 20 =	0		\$ 18	\$	0					
Independent claims	6	- 3 =	3	Х	\$ 88	\$	264					
MULTIPLE DEPENDEN	T CLAIM(S) (if	applicable)	TOTAL OF ABOV		\$	\$						
	\$											
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be												
filed (Note 37 CFR 1.9,	1.27, 1.28).				SUBTOTAL =	\$	264					
D	Confirmation at the	- 56-6	noncletion leter then			+Ψ	204					
Processing fee of \$130 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).								-				
TOTAL NATIONAL FEE =												
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied												
by an appropriate cover					+	\$	1,264					
TOTAL FEES ENCLOSED =												
							unt to be: refunded	\$				
					·- <del>-</del>		charged	\$				
a. A check in the	amount of \$		to cover the above t	ees is encl	osed.	-						
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.												
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently:												
Novartis Corporate Intelle One Health Plaz East Hanover, N DATED: JANU	za, Building 430 NJ 07936-1080	)	(A)	hñ T. Princ forney for <i>F</i> eg. No. 43,0 17) 871-33	Applicants 019 ·							